Transgenomic's Q1 Sales Sag 20 Percent as R&D Grows and Loss Widens | GenomeWeb
NEW YORK (GenomeWeb News) — Transgenomic yesterday said first-quarter revenues decreased 20 percent as R&D spending rose 75 percent and its net loss ballooned by 276 percent.
Total receipts for the three months ended March 31 fell to $5.2 million from $6.5 million year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.